Alternative Options to Minimize Niacin-Induced Flushing

Status Completed

Clinical Trial Summary

Niacin (Vitamin B3) is known to effectively and safely treat hypercholesterolemia. However, use of niacin is limited due to incidents of flushing which limits its acceptability. Some information suggests that applesauce can reduce the incidence and severity of flushing. The apple pectin in particular is thought to be the ingredient that affects this reaction. To determine if the apple pectin does affect flushing from niacin, the investigators will study the affects of isolated apple pectin in pill form. The investigators plan on recruiting 100 patients, and giving them 1000 mg of Niacin to induce flushing. Patients will be divided into 4 treatment groups and receive either pectin, aspirin, a combination of both, or placebo. Incidents and severity of flushing will be monitored for up to 6 hours post Niacin ingestion.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00895193
Study type	Interventional
Source	University of Kansas Medical Center
Contact
Status	Completed
Phase	N/A
Start date	January 2009
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04998695` - Health Effects of Consuming Olive Pomace Oil	N/A
Recruiting	`NCT03947866` - Ezetimibe-Rosuvastatin Evaluation Study
Completed	`NCT01709513` - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)	Phase 3
Completed	`NCT01212900` - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression	Phase 4
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed	`NCT02550288` - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Phase 3
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT04485793` - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia	N/A
Completed	`NCT02341924` - Validating the "Foods for Health" Portfolio of Functional Food Products	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Completed	`NCT01941836` - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients	Phase 2
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01678521` - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients	N/A
Completed	`NCT01670734` - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects	Phase 1
Completed	`NCT01370603` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)	Phase 3
Completed	`NCT01370590` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)	Phase 3
Completed	`NCT01768403` - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia	N/A
Completed	`NCT01575171` - Using Nudges to Implement Comparative Effectiveness	N/A
Completed	`NCT01446679` - Special Drug Use-Results Survey of Lipitor Tablets	N/A